**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 65294

**Manuscript Type:** CASE REPORT

**Oncocytic adrenocortical tumor with uncertain malignant potential in pediatric population: A case report and review of literature**

Chen XC *et al*. Oncocytic adrenocortical tumor

Xiao-Chun Chen, Yun-Man Tang, Yu Mao, Dao-Rui Qin

**Xiao-Chun Chen, Yun-Man Tang, Yu Mao, Dao-Rui Qin,** Department of Pediatric Surgery, Sichuan Academy of Medical Sciences Sichuan Provincial People's Hospital, Chengdu 610072, Sichuan Province, China

**Author contributions:** Chen XC and Qin DR designed the research study; Chen XC, Tang YM, Mao Y and Qin DR performed the research; Chen XC analyzed the data and wrote the manuscript; All authors have read and approve the final manuscript.

**Corresponding author: Dao-Rui Qin, PhD, Surgeon,** Department of Pediatric Surgery, Sichuan Academy of Medical Sciences Sichuan Provincial People's Hospital, No. 32 West Two Section, First Ring Road, Qingyang District, Chengdu 610072, Sichuan Province, China. daorui1982@163.com

**Received:** March 3, 2021

**Revised:** April 25, 2021

**Accepted:** May 8, 2021

**Published online:** July 16, 2021

**Abstract**

BACKGROUND

Oncocytic adrenocortical tumor (OACT) is rare, with few cases reported in the literature. No more than 20 cases in children have been reported. The clinical characteristics, diagnosis, treatment and prognosis of children with OACT are summarized based on a literature review, in order to improve the understanding of OACT in children.

CASE SUMMARY

We report a case of a 17-mo-old patient who was admitted to our hospital due to symptoms of odynuria and fever, which are clinical features consistent with a functional adrenocortical tumor. The patient was diagnosed with OACT of uncertain malignant potential. Computed tomography indicated a soft tissue giant tumor in the right adrenal region, approximately 4.3 cm × 5.5 cm in size. Multiple nodular and speckled calcifications were observed in the lesion. The patient received robot-assisted laparoscopic right adrenal tumor resection. Postoperative pathological results were consistent with OACT, and immunohistochemical results showed cytokeratin+/-, chromogranin A+, synaptophysin-, neuron-specific enolase-, S100-, Ki67 about 10%, CD34- and D2-40-. After surgery, urinary tract ultrasonography was reviewed monthly, catecholamine hormone and sex hormone levels were examined every 2 mo and computed tomography was performed every 6 mo. To date, no tumor metastasis or recurrence has been identified in this patient. The levels of sex hormones and catecholamine hormones decreased to normal 1 mo after surgery.

CONCLUSION

OACT is rare in the pediatric population, with few cases reported in the literature. Although most pediatric OACTs are benign, malignant cases have been reported. Surgical resection is the preferred option in most patients.

**Key Words:** Oncocytic adrenocortical tumor; Adrenocortical tumor; Robotic surgery; Children; Case report

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Chen XC, Tang YM, Mao Y, Qin DR. Oncocytic adrenocortical tumor with uncertain malignant potential in pediatric population: A case report and review of literature. *World J Clin Cases* 2021; 9(20): 5675-5682

URL: https://www.wjgnet.com/2307-8960/full/v9/i20/5675.htm

DOI: https://dx.doi.org/10.12998/wjcc.v9.i20.5675

**Core Tip:** Oncocytic adrenocortical tumor (OACT) is a very rare tumor, with few cases reported in the literature. Surgical resection is the preferred treatment option in most cases. We report the first case of robot-assisted laparoscopic resection of an OACT in a pediatric patient. The findings from this case report and the literature review show that robot-assisted laparoscopic resection of pediatric OACT with a complete tumor capsule, clear boundary between the tumor and surrounding tissues and no regional lymph node invasion is safe. Radiation and chemotherapy do not seem to be necessary in pediatric OACT without metastasis.

**INTRODUCTION**

Oncocytic adrenocortical tumor (OACT) is a very rare tumor[1]. At present, less than 200 cases have been reported[2]. Fewer than 20 pediatric patients have been reported worldwide[3-16]. OACT can be functional or nonfunctional, and most are nonfunctional[17]. Herein, we report a functional OACT with uncertain malignant potential in a 17-mo-old patient.

**CASE PRESENTATION**

***Chief complaints***

A 17-mo-old male patient was admitted to our hospital due to symptoms of odynuria and fever.

***History of present illness***

One day previously, the child showed no obvious cause of his urination pain, which was accompanied by fever, with a maximum temperature of 38.2 ℃.

***History of past illness***

The patient had no previous medical history.

***Personal and family history***

The patient had no specific personal and family history.

***Physical examination***

Forehead and the outer thighs showed scattered acne, and development of the penis and scrotum was more mature than his peers. Blood pressure was normal without significant fluctuations. No central obesity or other Cushing's syndrome signs were observed.

***Laboratory examinations***

Serum tumor marker examination revealed alpha-fetoprotein 5.40 ng/mL (< 8.78 ng/mL), cancer antigen-125 22.50 U/mL (< 35.0 U/mL), carbohydrate antigen 19-9 16.9 52 U/mL (< 34.0 U/mL), carcinoembryonic antigen 1.59 ng/mL (< 6.2 ng/mL) and neuron-specific enolase 43.26 ng/mL (< 20 ng/mL). Sex hormone levels were as follows: Dehydroepiandrosterone sulfate > 40.71 mol/L (3.7-16.1 mol/L), estradiol 87.6 pmol/L (40.4-161.5 pmol/L) and testosterone 12.97 nmol/L (4.94-32.01 nmol/L). Catecholamine hormone levels were as follows: Methoxy noradrenaline 1.22 nmol/L (< 0.90 nmol/L), 3-methoxytyramine 2.12 pg/mL (0-18.4 pg/mL), dopamine 0.01 nmol/L (< 0.02 nmol/L), adrenaline 0.04 nmol/L (0-0.77 nmol/L) methoxy adrenaline 0.03 nmol/L (< 0.05 nmol/L) and noradrenaline 3.15 nmol/L (0.41-10.06 nmol/L). The biochemical evaluation showed normal serum electrolyte levels.

***Imaging examinations***

Computed tomography showed a soft tissue tumor in the right adrenal region approximately 4.3 cm × 5.5 cm in size. There were multiple nodular and speckled calcifications in the lesion, which were considered to be tumor occupying changes. Photographs showed that the patient’s bone age was ahead of schedule (Figure 1).

***Pathology and immunohistochemical examination***

Pathology and immunohistochemistry confirmed an adrenocortical tumor of oncocytic subtype, with a maximum diameter of about 5.5 cm. Postoperative tissue is shown in Figure 2, and a microscopic image is shown in Figure 3. Eosinophils were predominant; clear cells were < 25% with visible atypical wide cells. No definite necrosis, capsular invasion or vein invasion were found. Visible focal sinus infiltration was identified, nuclear fission image count was 1/10 hibernation-promoting factor (HPF) and reticular fiber staining was noted showing partial damage. Immunohistochemical results were as follows: Cytokeratin+/-, chromogranin A+, synaptophysin-, neuron-specific enolase-, S100-, Ki67 about 10%, CD34- and D2-40-. According to the World Health Organization 2016/4thE Lin-Weiss-Bisceglia standard, the tumor was considered an OACT with uncertain malignant potential.

**FINAL DIAGNOSIS**

Malignant features in oncocytic adrenocortical tumor are determined using the World Health Organization 2016/4thE Lin–Weiss–Bisceglia criteria, the patient was finally diagnosed as an OACT with uncertain malignant potential.

**TREATMENT**

The maximum diameter of the tumor was 5.5 cm, and it was confirmed to be an OACT. The patient underwent robot-assisted laparoscopic right adrenal tumor resection.

**OUTCOME AND FOLLOW-UP**

During the follow-up, urinary tract ultrasonography was reviewed monthly, catecholamine hormone and sex hormone levels were examined every 2 mo and CT was performed every 6 mo. To date, no tumor metastasis or recurrence has been identified. The sex hormone and catecholamine hormone levels reduced to normal 1 mo after surgery.

**DISCUSSION**

At present, the etiology of OACT is still unclear. Kakimoto *et al*[18] were the first to report an OACT in 1986. Oncocytic tumors are neoplasms composed predominantly of cells with abundant granular, eosinophilic cytoplasm termed “oncocytes”. These cytoplasmic changes are attributed to the abundant mitochondria[19]. Gasparre *et al*[20] believed that the increase in mitochondria in this disease is a compensatory reaction to cellular dysfunction, which may be due to the excessive proliferation of mitochondrial DNA without corresponding transcription of RNA, resulting in the excessive increase of mitochondria in cells[20].

Limited reports on OACT epidemiology were found in the literature review. Available statistics are from an epidemiological study by Kanitra *et al*[21] that included 140 OACT patients, 66% were found in female patients, 64% were found in the left adrenal gland and 66% were nonfunctional. The mean age at diagnosis was 44 years (2.5-77 years), and the mean tumor size was 80 mm (16-285 mm). A total of 35% were benign, 41% were of uncertain malignant potential and 24% were malignant. Compared with female patients, male patients were more likely to develop malignancy (36% *vs* 18%, *P* = 0.035). The 5-year overall survival rate of benign OACT was 100%, was 88% in those with uncertain malignant potential and 47% in those with malignant potential[21]. However, there are limitations in the statistics, which did not include children under 2.5 years. There are no epidemiological data for large populations of children, as only a few cases have been reported.

An OACT can be functional or nonfunctional, most of which are nonfunctional and only a few are functional[17], resulting in pseudopuberty, gynecomastia, virilization, feminization and Cushing's syndrome[22,23].Advanced bone age has also been reported in children[13]. Details of children with OACT are shown in Table 1.

Clinical manifestations, auxiliary examination and tumor size are limited in the diagnosis of OACT, and the Weiss criteria are not completely reliable for the diagnosis of OACT[24]. Bisceglia *et al*[17] improved the Weiss criteria according to the pathological characteristics of OACT. At present, the Lin Weiss Bisceglia (LWB) criteria are commonly used in the pathological diagnosis of OACT: OACTs that meet any of the following major criteria are classified as malignant: Mitotic rate > 5 *per* 50 HPF, atypical mitoses and venous invasion. OACTs that meet any of the following secondary criteria are classified as having uncertain malignant potential; larger size (> 10 cm and/or weight > 200 g), necrosis, capsular invasion or sinusoidal infiltration. In the absence of major or secondary criteria, OACTs are considered benign[21]. In the present case, the tumor was nodular, 5.5 cm × 5.0 cm × 3.0 cm in size with a complete capsule, the section was gray-yellow and soft and calcification was visible, with no obvious bleeding and necrosis. No definite capsular invasion, vascular invasion or focal sinus infiltration were observed, and the mitotic count was one *per* 10 HPF. Histologically, one item met the secondary criteria; thus, it was considered an OACT with uncertain malignant potential.

Pathological examination is helpful in the diagnosis of pediatric OACT. A typical OACT is dark brown. In the present case, under a light microscope, the tumor cells were the same size, with low-fat droplets of granular and oncocytic cytoplasm. The nucleus was in the center, arranged into a beam-like and hollow tubular structure, occasionally forming microcapsules surrounded by thin fibrous septa, and a small amount of lymphocytes infiltrated the mesenchyme. Under an electron microscope, there were a number of mitochondria with lamellar and tubulovesicular cristae and small electron dense inclusion bodies in the cytoplasm. OACTs rarely show mitosis and necrosis[25]. At present, the LWB criteria are commonly used in the pathological diagnosis of children with OACT. The pathological findings in this case were consistent with the diagnosis of OACT. Following immunohistochemical analysis, eosinophilic cells were markedly and diffusely positive for vimentin, steroidogenic factor 1, alpha-inhibin, Melan A, synaptophysin, neuron-specific enolase and CD56[26]. Equilibrative nucleoside transporter 1 and synaptophysin are the two most specific markers in OACT[27].

Surgical resection is the main treatment for OACT, and long-term follow-up is required. Traditional open surgery is established. However, with the development and popularization of laparoscopic technology, this technology is more commonly adopted for the resection of adrenal cortical tumors. At present, robot-assisted laparoscopic resection of adrenal cortical tumors has not been reported. In 2014, Akin *et al*[9] reported the first laparoscopic resection of an OACT in children[9]. However, whether laparoscopic adrenalectomy should be used for potential malignancies with tumor diameter > 6 cm is controversial. Up to now the consensus has been to restrict the endoscopic approach to adrenal tumors measuring < 5 to 6 cm in diameter[28]. We believe that robot-assisted laparoscopic resection of OACT with a complete tumor capsule, clear boundary between the tumor and surrounding tissue and no regional lymph node invasion is safe in pediatric patients. Radiotherapy and chemotherapy have been reported for metastatic OACT[29]. In children with OACT without metastasis, there may be no need for radiotherapy or chemotherapy. OACTs are mostly benign tumors, but there are also reports of malignancy. Contrary to previous literature, John *et al*[30] found that the majority of adrenocortical oncocytic neoplasms (65%) were either malignant or had malignant potential. Hormone function cannot distinguish benign from malignant or prognosis. However, the majority of OACTs that are synaptophysin positive (50%, *P* < 0.001) and vimentin negative (62%, *P* = 0.009) were benign[21]. It has also been reported that Ki67 can reflect the degree of malignancy and the prognosis of OACT[31,32]. To date, no tumor metastasis or recurrence has been identified in the present case.

**CONCLUSION**

OACTs in children are rare. There are a few reports on pediatric OACTs, and the etiology is still unclear. Most OACTs are nonfunctional benign tumors, but there are also reports of malignancy. The LWB criteria are commonly used for the diagnosis of pediatric OACTs, and the diagnosis is mainly based on histological and pathological examination. Equilibrative nucleoside transporter 1 and synaptophysin are two of the most specific markers in eosinophilic tumors. Radical resection is the key to early treatment. We believe that robot-assisted laparoscopic resection of pediatric OACT with a complete tumor capsule, clear boundary between the tumor and surrounding tissues and no regional lymph node invasion is safe. Children with OACT do not seem to require radiotherapy and chemotherapy. Ki67 can reflect the degree of malignancy and the prognosis of OACT.

**REFERENCES**

1 **Ohtake H**, Kawamura H, Matsuzaki M, Yokoyama E, Kitajima M, Onizuka S, Yamakawa M. Oncocytic adrenocortical carcinoma. *Ann Diagn Pathol* 2010; **14**: 204-208 [PMID: 20471567 DOI: 10.1016/j.anndiagpath.2009.06.006]

2 **Yan K**, Xu X, Liu X, Wang X, Hua S, Wang C, Liu X. Corrigendum: The Associations Between Maternal Factors During Pregnancy and the Risk of Childhood Acute Lymphoblastic Leukemia: A Meta-Analysis. *Pediatr Blood Cancer* 2016; **63**: 953-954 [PMID: 26999072 DOI: 10.1002/pbc.25962]

3 **Gumy-Pause F**, Bongiovanni M, Wildhaber B, Jenkins JJ, Chardot C, Ozsahin H. Adrenocortical oncocytoma in a child. *Pediatr Blood Cancer* 2008; **50**: 718-721 [PMID: 17091483 DOI: 10.1002/pbc.21090]

4 **Lim YJ**, Lee SM, Shin JH, Koh HC, Lee YH. Virilizing adrenocortical oncocytoma in a child: a case report. *J Korean Med Sci* 2010; **25**: 1077-1079 [PMID: 20592902 DOI: 10.3346/jkms.2010.25.7.1077]

5 **Tahar GT**, Nejib KN, Sadok SS, Rachid LM. Adrenocortical oncocytoma: a case report and review of literature. *J Pediatr Surg* 2008; **43**: E1-E3 [PMID: 18485928 DOI: 10.1016/j.jpedsurg.2007.12.067]

6 **Subbiah S**, Nahar U, Samujh R, Bhansali A. Heterosexual precocity: rare manifestation of virilizing adrenocortical oncocytoma. *Ann Saudi Med* 2013; **33**: 294-297 [PMID: 23793435 DOI: 10.5144/0256-4947.2013.294]

7 **Kawahara Y**, Morimoto A, Onoue A, Kashii Y, Fukushima N, Gunji Y. Persistent fever and weight loss due to an interleukin-6-producing adrenocortical oncocytoma in a girl--review of the literature. *Eur J Pediatr* 2014; **173**: 1107-1110 [PMID: 24610396 DOI: 10.1007/s00431-014-2292-8]

8 **Yoon JH**, Cha SS, Yoon SK. Computed tomography and magnetic resonance images of adrenocortical oncocytoma cases. *J Korean Med Sci* 2014; **29**: 445-451 [PMID: 24616598 DOI: 10.3346/jkms.2014.29.3.445]

9 **Akin M**, Erginel B, Tanik C, Akinci N, Yildiz A, Beker B, Karadag CA, Sever N, Turk S, Dokucu AI. The first laparo- scopic resection of an aldosterone-secreting adrenocortical oncocytoma in a child. *J Pediatr Surg Case Rep* 2014; **2**: 424–427 [DOI: 10.1016/j.epsc.2014.08.002]

10 **Ranganathan S**, Lynshue K, Hunt JL, Kane T, Jaffe R. Unusual adrenal cortical tumor of unknown biologic potential: a nodule in a nodule in a nodule. *Pediatr Dev Pathol* 2005; **8**: 483-488 [PMID: 16010500 DOI: 10.1007/s10024-005-1123-3]

11 **Mardi K**. Virilizing adrenocortical oncocytic neoplasm with uncertain malignant potential in a child: A rare case report. *Indian J Cancer* 2016; **53**: 203-204 [PMID: 27146779 DOI: 10.4103/0019-509X.180848]

12 **Chen GX**, Zhang XS, Li ZH, Gong ZQ. Clinicopathological Features and Minimal Invasive Management of Oncocytic Adrenal Neoplasm. *Zhongguo Weichuangwaike Zazhi* 2018; **18**: 694-698 [DOI: 10.3969/j.issn.1009-6604.2018.08.006]

13 **Yordanova G**, Iotova V, Kalchev K, Ivanov K, Balev B, Kolev N, Tonev A, Oosterhuis W. Virilizing adrenal oncocytoma in a 9-year-old girl: rare neoplasm with an intriguing postoperative course. *J Pediatr Endocrinol Metab* 2015; **28**: 685-690 [PMID: 25514324 DOI: 10.1515/jpem-2014-0308]

14 **Pereira BD**, Rios ES, Cabrera RA, Portugal J, Raimundo L. Adrenocortical oncocytoma presenting as Cushing's syndrome: an additional report of a paediatric case. *Endocr Pathol* 2014; **25**: 397-403 [PMID: 25077961 DOI: 10.1007/s12022-014-9325-8]

15 **Kolev NY**, Ignatov VL, Tonev AY, Zlatarov AK, Encheva EP, Kirilova TN, VM Bojkov VM, Ivanov KD. Adrenal oncocytoma in children—Case report. *J IMAB* 2013; **19**:470–472 [DOI: 10.5272/jimab.2013193.470]

16 **Agarwal S**, Agarwal K. Rare pediatric adrenocortical carcinoma with oncocytic change: a cytologic dilemma. *Endocr Pathol* 2011; **22**: 40-43 [PMID: 21181300 DOI: 10.1007/s12022-010-9142-7]

17 **Bisceglia M**, Ludovico O, Di Mattia A, Ben-Dor D, Sandbank J, Pasquinelli G, Lau SK, Weiss LM. Adrenocortical oncocytic tumors: report of 10 cases and review of the literature. *Int J Surg Pathol* 2004; **12**: 231-243 [PMID: 15306935 DOI: 10.1177/106689690401200304]

18 **Kakimoto S**, Yushita Y, Sanefuji T, Kondo A, Fujishima N, Kishikawa M, Matsumoto K. Non-hormonal adrenocortical adenoma with oncocytoma-like appearances. *Hinyokika Kiyo* 1986; **32**: 757-763 [PMID: 3751804]

19 **Ertan Y**, Argon A, Özdemir M, Yürekli BPS, Dökümcü Z, Makay Ö. Oncocytic Adreno Cortical Tumors: Pathological Features of 16 Cases and Review of the Literature. *J Environ Pathol Toxicol Oncol* 2017; **36**: 237-244 [PMID: 29283337 DOI: 10.1615/JEnvironPatholToxicolOncol.2017021895]

20 **Gasparre G**, Bonora E, Tallini G, Romeo G. Molecular features of thyroid oncocytic tumors. *Mol Cell Endocrinol* 2010; **321**: 67-76 [PMID: 20184940 DOI: 10.1016/j.mce.2010.02.022]

21 **Kanitra JJ**, Hardaway JC, Soleimani T, Koehler TJ, McLeod MK, Kavuturu S. Adrenocortical oncocytic neoplasm: A systematic review. *Surgery* 2018; **164**: 1351-1359 [PMID: 30037428 DOI: 10.1016/j.surg.2018.04.044]

22 **Geramizadeh B**, Norouzzadeh B, Bolandparvaz S, Sefidbakht S. Functioning adrenocortical oncocytoma: a case report and review of literature. *Indian J Pathol Microbiol* 2008; **51**: 237-239 [PMID: 18603692 DOI: 10.4103/0377-4929.41667]

23 **Xiao GQ**, Pertsemlidis DS, Unger PD. Functioning adrenocortical oncocytoma: a case report and review of the literature. *Ann Diagn Pathol* 2005; **9**: 295-297 [PMID: 16198960 DOI: 10.1016/j.anndiagpath.2005.05.005]

24 **Li F**, Wang JJ, Deng HY, Zhang LL, Ding Y, Liu Y, Zhang M, Liu YP. New classification of adrenal endocrine tumors by WHO. *Linchuang Yu Shiyanbinglixue Zazhi* 2018; **34**: 709-713 [DOI: 10.13315/j.cnki.cjcep.2018.07.001]

25 **Liao WF**, Ma LL. Eosinophiloma of the adrenal cortex: a case report. *Oncology* 2012; **39**: 179 [DOI: 10.3969/j.issn.1000-8179.2012.03.016]

26 **Kasajima A**, Nakamura Y, Adachi Y, Takahashi Y, Fujishima F, Chiba Y, Uehara S, Watanabe M, Sasano H. Oncocytic adrenocortical neoplasm arising from adrenal rest in the broad ligament of the uterus. *Pathol Int* 2014; **64**: 183-188 [PMID: 24750189 DOI: 10.1111/pin.12154]

27 **Li H**, Hes O, MacLennan GT, Eastwood DC, Iczkowski KA. Immunohistochemical distinction of metastases of renal cell carcinoma to the adrenal from primary adrenal nodules, including oncocytic tumor. *Virchows Arch* 2015; **466**: 581-588 [PMID: 25690138 DOI: 10.1007/s00428-015-1732-9]

28 **Henry JF**, Sebag F, Iacobone M, Mirallie E. Results of laparoscopic adrenalectomy for large and potentially malignant tumors. *World J Surg* 2002; **26**: 1043-1047 [PMID: 12045859 DOI: 10.1007/s00268-002-6666-0]

29 **Tanaka K**, Kumano Y, Kanomata N, Takeda M, Hara I, Fujisawa M, Kawabata G, Kamidono S. Oncocytic adrenocortical carcinoma. *Urology* 2004; **64**: 376-377 [PMID: 15302503 DOI: 10.1016/j.urology.2004.04.023]

30 **Ahmed MA**, Sureshkannan KS, Raouf ZR, Koliyadan SV, Grant CS, Al-Habsi AH, Saparamadu PA, Al-Sajee D. Adrenal oncocytic neoplasm with uncertain malignant potential. *Sultan Qaboos Univ Med J* 2013; **13**: E334-E338 [PMID: 23862048 DOI: 10.12816/0003248]

31 **Papathomas TG**, Pucci E, Giordano TJ, Lu H, Duregon E, Volante M, Papotti M, Lloyd RV, Tischler AS, van Nederveen FH, Nose V, Erickson L, Mete O, Asa SL, Turchini J, Gill AJ, Matias-Guiu X, Skordilis K, Stephenson TJ, Tissier F, Feelders RA, Smid M, Nigg A, Korpershoek E, van der Spek PJ, Dinjens WN, Stubbs AP, de Krijger RR. An International Ki67 Reproducibility Study in Adrenal Cortical Carcinoma. *Am J Surg Pathol* 2016; **40**: 569-576 [PMID: 26685085 DOI: 10.1097/PAS.0000000000000574]

32 **Erickson LA**. Challenges in surgical pathology of adrenocortical tumours. *Histopathology* 2018; **72**: 82-96 [PMID: 29239032 DOI: 10.1111/his.13255]

**Footnotes**

**Informed consent statement:** Written informed consent was obtained from the patients for publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors have nothing to disclose.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** March 3, 2021

**First decision:** April 14, 2021

**Article in press:** May 8, 2021

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Keikha M **S-Editor:** Fan JR **L-Editor:** Filipodia **P-Editor:** Li JH


**Figure Legends**



**Figure 1 The ossification center indicates 3-year-old bone age changes.**



**Figure 2 Complete tumor capsule, tumor size 5.5 cm × 5.0 cm × 3.0 cm, no definite capsular invasion and no definite vein invasion were found.**



**Figure 3 Eosinophils were predominant; visible wide cell atypical; no definite necrosis was found; no definite capsular invasion was found; no definite vein violation; visible focal sinus infiltration; some calcification is visible.** A: Typical eosinophilic changes (hematoxylin-eosin staining, image at 400 × magnification); B: This is a focal sinus infiltration of eosinophils (hematoxylin-eosin staining, image at 400 × magnification). Yellow arrow: Focal sinus infiltration; C: Calcification: Blue fine particles aggregate (hematoxylin-eosin staining, image at 400 × magnification). Blue arrow: Calcification; D: Mitotic images count 1/10 hibernation-promoting factor (hematoxylin-eosin staining, image at 400 × magnification). Green arrow: Mitotic nuclear division.

**Table 1 Cases of oncocytic adrenocortical tumor in children reported in the literature**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Age in yr** | **G** | **Clinical features** | **Size** | **Treatment** | **Follow-up** | **Prognosis** |
| Gumy-Pause *et al*[3], 2008 | 12 | F | Fatigue, headache, acne vulgaris, and abdominal pain | 5.0 cm × 4.3 cm × 2.2 cm | Open adrenalectomy | Normal hormone levels 18 mo after diagnosis | No recurrence |
| Lim *et al*[4], 2010 | 14 | F | Deepening of the voice and excessive hair | 17.5 cm × 15 cm × 14 cm | Open adrenalectomy | Normal hormone levels 2 wk after operative resection | No recurrence |
| Tahar *et al*[5], 2008 | 6 | F | Precocious puberty | 3.0 cm × 2.0 cm × 1.5 cm | Open adrenalectomy | 12 mo after operative resection, he manifestations of pseudoprecocious puberty were effectively reduced | No recurrence |
| Subbiah *et al*[6], 2013 | 3 1/2 | F | Premature pubarche, clitoromegaly | 2.5 cm × 2.0 cm | Open adrenalectomy | Normal hormone levels 1 mo after operative resection | No recurrence |
| Kawahara *et al*[7], 2014 | 11 | F | Fever, weight loss,  increased inflammatory markers | 4.5 cm × 4.5 cm × 2.5 cm | Open adrenalectomy | The inflammatory markers and IL-6 levels normalized within 2 wk after tumor resection | No recurrence |
| Yoon *et al*[8], 2014 | 10 | F | Precocious puberty | 6.0 cm × 4.0 cm | Open adrenalectomy | 1 yr after surgery without new lesions | No recurrence |
| Akin *et al*[9], 2014 | 11 | M | Metabolic, alkalosis, polyuria, polydipsia, hypokalemia | 4.5 cm × 3.5 cm × 2.5 cm | Laparoscopic surgery | After the operation, the patient's polyuria and hypokalemia resolved, and his aldosterone level returned to normal | No recurrence |
| Ranganathan *et al*[10], 2005 | 5 | M | Precocious puberty, acne | 4.2 cm × 3.9 cm × 2.6 cm | Laparoscopic surgery | 3 mo later, the patient had lost 3.2 kg and had grown 3.5 cm. Clinically, his symptoms resolved with no progression of pubic hair, axillary hair, or acne | No recurrence |
| Mardi *et al*[11], 2016 | 14 | F | Hirsuitism | 18 cm × 8.0 cm × 7.0 cm | Open adrenalectomy | The hirsuitism resolved gradually following surgery | No recurrence |
| Chen *et al*[12], 2018 | 15 | M | Lower back pain | 9.0 cm × 6.3 cm | Laparoscopic surgery | Lower back pain relief | No recurrence |
| Yordanova *et al*[13], 2015 | 9 | F | Virilization | 2.2 cm × 2.2 cm | Laparoscopic surgery | 11 mo after the surgery, the girl’s appearance was less masculine, with significantly reduced body hairs but still no changes in the voice | No recurrence |
| Pereira *et al*[14], 2014 | 5.8 | F | Weight gain, precocious puberty | 3.2 cm × 4.5 cm | Open adrenalectomy | The patient is in complete remission after 64 mo of follow-up | No recurrence |
| Kolev *et al*[15], 2013 | 9 | F | Deepening of the  voice and excessive hair | 3.0 cm × 2.8 cm × 3.5 cm | Laparoscopic surgery | Normal hormone levels 2 wk after operative resection | No recurrence |
| Agarwal *et al*[16], 2011 | 2.5 | F | Virilization | - | Open adrenalectomy, biopsy | Poor prognosis | No resection, infiltration into adjacent organs |
| Current case | 17 mo | M | Odynuria, fever | 5.5 cm × 5.0 cm × 3.0 cm | Robot assisted laparoscopic operation | Normal hormone levels 1 mo after operative resection | No recurrence |

F: Female; G: Gender; IL-6: Interleukin 6; M: Male.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**